Ichiro Takata

Daily low-dose cisplatin and concurrent thoracic irradiation for poor-risk patients with unresectable non-small-cell lung cancer. (2006)

Takata, Ichiro, Ueoka, Hiroshi, Kiura, Katsuyuki, Tabata, Masahiro, Takigawa, Nagio, Katayama, Hideki, ...

A pilot study was conducted to assess the efficacy and feasibility of daily low-dose cisplatin with concurrent thoracic irradiation for clinically unresectable non-small-cell lung cancer (NSCLC)....

Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected] (2003)

Yano, Seiji, Giaccone, Giuseppe, Tamura, Tomohide, Nakagawa, Kazuhiko, Douillard, Jean-Yves, ...

PURPOSE: To evaluate the efficacy and tolerability of two doses of gefitinib (Iressa [ZD1839]; AstraZeneca, Wilmington, DE), a novel epidermal growth factor receptor tyrosine kinase inhibitor, in...

A Case of Recurrent Metastatic Thymoma Showing a Marked Response to Paclitaxel Monotherapy (2002)

Umemura, Shigeki, Segawa, Yoshihiko, Fujiwara, Keiichi, Takata, Ichiro, Seki, Nobuhiko, Tokuda, Yoshiyuki, ...

We describe a case of recurrent metastatic thymoma showing an excellent response to salvage paclitaxel monotherapy. The patient had undergone a series of platinum-based chemotherapy treatments during...

(-)-Epigallocatechin gallate can prevent cisplatin-induced lung tumorigenesis in A/J mice (2000)

Mimoto, Junko, Kiura, Katsuyuki, Matsuo, Keisuke, Yoshino, Tadashi, Takata, Ichiro, Ueoka, Hiroshi, ...

Risks of secondary lung cancer in patients with non-small cell lung cancer and small cell lung cancer are estimated to be 1–2% and 2–10% per patient per year, respectively. Cisplatin is widely...